Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features

被引:18
作者
Rommasi, Foad [1 ]
Nasiri, Mohammad Javad [2 ]
Mirsaeidi, Mehdi [3 ]
机构
[1] Shahid Beheshti Univ, Fac Life Sci & Biotechnol, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran
[3] Univ Miami, Miller Sch Med, Dept Pulm & Crit Care, Miami, FL 33136 USA
关键词
SARS-CoV-2; Pathophysiology; COVID-19; treatment; Inflammatory responses; Immunosuppressive agents; Cytokine storm; NECROSIS-FACTOR-ALPHA; CORONAVIRUS DISEASE 2019; RHEUMATOID-ARTHRITIS; CLINICAL PHARMACOKINETICS; RECEPTOR ANTAGONIST; IN-VITRO; ABSOLUTE BIOAVAILABILITY; COLCHICINE THERAPY; CYTOKINE STORM; MELATONIN;
D O I
10.1007/s11010-021-04325-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The novel coronavirus pandemic has emerged as one of the significant medical-health challenges of the current century. The World Health Organization has named this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first detection of SARS-CoV-2 in November 2019 in Wuhan, China, physicians, researchers, and others have made it their top priority to find drugs and cures that can effectively treat patients and reduce mortality rates. The symptoms of Coronavirus Disease 2019 (COVID-19) include fever, dry cough, body aches, and anosmia. Various therapeutic compounds have been investigated and applied to mitigate the symptoms in COVID-19 patients and cure the disease. Degenerative virus analyses of the infection incidence and COVID-19 have demonstrated that SARS-CoV-2 penetrates the pulmonary alveoli's endothelial cells through Angiotensin-Converting Enzyme 2 (ACE2) receptors on the membrane, stimulates various signaling pathways and causes excessive secretion of cytokines. The continuous triggering of the innate and acquired immune system, as well as the overproduction of pro-inflammatory factors, cause a severe condition in the COVID-19 patients, which is called "cytokine storm". It can lead to acute respiratory distress syndrome (ARDS) in critical patients. Severe and critical COVID-19 cases demand oxygen therapy and mechanical ventilator support. Various drugs, including immunomodulatory and immunosuppressive agents (e.g., monoclonal antibodies (mAbs) and interleukin antagonists) have been utilized in clinical trials. However, the studies and clinical trials have documented diverging findings, which seem to be due to the differences in these drugs' possible mechanisms of action. These drugs' mechanism of action generally includes suppressing or modulating the immune system, preventing the development of cytokine storm via various signaling pathways, and enhancing the blood vessels' diameter in the lungs. In this review article, multiple medications from different drug families are discussed, and their possible mechanisms of action are also described.
引用
收藏
页码:711 / 726
页数:16
相关论文
共 161 条
  • [1] Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in PatientsWith Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
    Abdallah, Hisham
    Hsu, Joy C.
    Lu, Peng
    Fettner, Scott
    Zhang, Xiaoping
    Douglass, Wendy
    Bao, Min
    Rowell, Lucy
    Burmester, Gerd R.
    Kivitz, Alan
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (04) : 459 - 468
  • [2] Ahmed, 2020, J ADV MED MED RES, DOI [10.9734/jammr/2020/v32i430393, DOI 10.9734/JAMMR/2020/V32I430393]
  • [3] Akiho Hirotada, 2015, World J Gastrointest Pathophysiol, V6, P219, DOI 10.4291/wjgp.v6.i4.219
  • [4] Alpa, 2015, REACTIONS, V1580, P32
  • [5] American Society of Health-System Pharmacists (ASHP), 2021, NAPR
  • [6] Baricitinib
    不详
    [J]. AUSTRALIAN PRESCRIBER, 2019, 42 (01) : 34 - 35
  • [7] [Anonymous], 2012, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]
  • [8] Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist
    Arend, WP
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2001, 30 (05) : 1 - 6
  • [9] BIOLOGICAL PROPERTIES OF RECOMBINANT HUMAN MONOCYTE-DERIVED INTERLEUKIN-1 RECEPTOR ANTAGONIST
    AREND, WP
    WELGUS, HG
    THOMPSON, RC
    EISENBERG, SP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (05) : 1694 - 1697
  • [10] INHIBITION OF THE PRODUCTION AND EFFECTS OF INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR-ALPHA IN RHEUMATOID-ARTHRITIS
    AREND, WP
    DAYER, JM
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (02): : 151 - 160